Metraipolis › archive › dc_ed87c83fbb11

Clinical outcomes of sotrovimab in seronegative patients with severe COVID-19: A multicenter retrospective study — Europe PMC PMID:41496008

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41496008
DOI
10.1097/md.0000000000046382
License (as archived)
solo-consultazione
Archived
2026-11-07T04:38:44.811Z
SHA-256 of the archived text
418aa6d3d7859eb99f3e07619a6ee1684434303c78d525f3cef65c6bcd5ee29e
Stable URL of this page
https://metraipolis.com/documento/dc_ed87c83fbb11

How to cite

Clinical outcomes of sotrovimab in seronegative patients with severe COVID-19: A multicenter retrospective study — Europe PMC PMID:41496008 — Europe PMC (en), https://europepmc.org/article/MED/41496008 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ed87c83fbb11 (Metraipolis archive dc_ed87c83fbb11, sha256 418aa6d3d7859eb99f3e07619a6ee1684434303c78d525f3cef65c6bcd5ee29e)
BibTeX
@misc{dced87c83fbb11,
  title = {Clinical outcomes of sotrovimab in seronegative patients with severe COVID-19: A multicenter retrospective study — Europe PMC PMID:41496008},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41496008},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ed87c83fbb11; sha256 418aa6d3d7859eb99f3e07619a6ee1684434303c78d525f3cef65c6bcd5ee29e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41496008. Agents can read the archived copy with the MCP tool read_document.